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Abstract—Fatty acid amide hydrolase (FAAH) catalyses hy-
drolysis of the endocannabinoid arachidonoylethanolamide
(“anandamide”) in vitro and regulates anandamide levels in
the brain. In the cerebellar cortex, hippocampus and neocor-
tex of the rat brain, FAAH is located in the somata and
dendrites of neurons that are postsynaptic to axon ﬁbers
expressing the CB1 cannabinoid receptor [Proc R Soc Lond B
265 (1998) 2081]. This complementary pattern of FAAH and
CB1 expression provided the basis for a hypothesis that
endocannabinoids may function as retrograde signaling mol-
ecules at synapses in the brain [Proc R Soc Lond B 265 (1998)
2081; Phil Trans R Soc Lond 356 (2001) 381] and subsequent
experimental studies have conﬁrmed this [Science 296 (2002)
678]. To assess more widely the functions of FAAH in the
brain and the potential impact of FAAH activity on the spa-
tiotemporal dynamics of endocannabinoid signaling in differ-
ent regions of the brain, here we have employed immunocy-
tochemistry to compare the distribution of FAAH and CB1
throughout the mouse brain, using FAAH
/ mice as negative
controls to validate the speciﬁcity of FAAH-immunoreactivity
observed in wild type animals. In many regions of the brain,
a complementary pattern of FAAH and CB1 expression was
observed, with FAAH-immunoreactive neuronal somata and
dendrites surrounded by CB1-immunoreactive ﬁbers. In
these regions of the brain, FAAH may regulate postsynaptic
formation of anandamide, thereby inﬂuencing the spatiotem-
poral dynamics of retrograde endocannabinoid signaling.
However, in some regions of the brain such as the globus
pallidus and substantia nigra pars reticulata, CB1 receptors
are abundant but with little or no associated FAAH expres-
sion and in these brain regions the spatial impact and/or
duration of endocannabinoid signaling may be less restricted
than in regions enriched with FAAH. A more complex situa-
tion arises in several regions of the brain where both FAAH
and CB1 are expressed but in a non-complementary pattern,
with FAAH located in neurons and/or oligodendrocytes that
are proximal but not postsynaptic to CB1-expressing axon
ﬁbers. Here FAAH may nevertheless inﬂuence endocannabi-
noid signaling but more remotely. Finally, there are regions of
the brain where FAAH-immunoreactive neurons and/or oligo-
dendrocytes occur in the absence of CB1-immunoreactive
ﬁbers and here FAAH may be involved in regulation of sig-
naling mediated by other endocannabinoid receptors or by
receptors for other fatty acid amide signaling molecules. In
conclusion, by comparing the distribution of FAAH and CB1
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regulation of the spatiotemporal dynamics of retrograde en-
docannabinoid signaling in different regions of the brain.
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Fatty acid amide hydrolase (FAAH) is a membrane-asso-
ciated enzyme that was ﬁrst isolated from rat liver on
account of its ability to catalyze hydrolysis of the sleep-
inducing lipid oleamide (Cravatt et al., 1995, 1996). Anal-
ysis of the substrate selectivity of FAAH revealed, how-
ever, that it also hydrolyzes anandamide (arachidonoyleth-
anolamide), a putative endogenous ligand for the CB1-type
cannabinoid receptor in the brain (Cravatt et al., 1996).
2-Arachidonylglycerol (2-AG), a second putative endocan-
nabinoid, also appears to be reactive with FAAH in vitro
(Goparaju et al., 1998) and therefore these data indicate
that FAAH might be generally required for inactivation of
endocannabinoids in the brain. Evidence in support of this
was provided by the detection of FAAH in brain tissue and
localization of FAAH expression in neurons of the rat brain
(Cravatt et al., 1996; Giang and Cravatt, 1997; Thomas et
al., 1997; Egertova ´ et al., 1998; Tsou et al., 1998). More-
over, recently mice lacking the FAAH gene have been
generated and analysis of these animals has demon-
strated that FAAH controls endogenous anandamide lev-
els in the brain and attenuates the behavioral effects of
exogenous anandamide (Cravatt et al., 2001). Interest-
ingly, however, analysis of mice lacking FAAH indicates
that FAAH is not responsible for regulating 2-AG in vivo
(Lichtman et al., 2002), and consistent with this idea, the
enzyme monoglyceride lipase is now thought to be the
main enzyme involved in inactivation of 2-AG in the brain
(Dinh et al., 2002).
The potential for FAAH to exert a regulatory inﬂuence
on endocannabinoid signaling at a synaptic level has been
investigated by using immunocytochemistry to compare
the distribution of FAAH and the CB1 receptor in selected
regions of the rat brain (Egertova ´ et al., 1998). Importantly,
FAAH is localized in the somata and dendrites of principal
neurons in the cerebellar cortex (Purkinje cells), hippocam-
pus (pyramidal cells) and the neocortex (pyramidal cells).
Moreover, in each of these brain regions there is a com-
plementary pattern of cannabinoid receptor expression,
with CB1 targeted to the axon terminals of neurons that are
presynaptic to the FAAH-expressing principal cells. Detec-
tion of FAAH in the somato-dendritic compartment of neu-
rons that are postsynaptic to CB1-expressing axons led us
to propose a model of endocannabinoid signaling in which
endocannabinoids are both synthesized and inactivated
postsynaptically and function as retrograde synaptic mes-
senger molecules that act on presynaptic CB1 receptors to
inhibit release of “classical” neurotransmitters (Egertova ´e t
al., 1998; Elphick and Egertova ´, 2001).
Recently, several studies have demonstrated that en-
docannabinoids do indeed act as retrograde signals at
synapses in the brain (reviewed in Maejima et al., 2001a;
Wilson and Nicoll, 2002; Kreitzer and Regehr, 2002). In
particular, Wilson and Nicoll (2001) and Ohno-Shosaku et
al. (2001) showed that endocannabinoids mediate a retro-
grade signal from depolarized hippocampal pyramidal cells
to presynaptic GABAergic axon terminals that causes sup-
pression of inhibitory input (depolarization-induced sup-
pression of inhibition or DSI). Similarly, Kreitzer and Re-
gehr (2001a) reported that depolarization-induced sup-
pression of excitation (DSE) in the cerebellar cortex is
mediated by a retrograde endocannabinoid signal from
depolarized Purkinje cells to presynaptic glutamatergic
parallel ﬁbers. Because FAAH is expressed in neurons that
generate endocannabinoids (e.g. hippocampal pyramidal
cells and Purkinje cells; Egertova ´ et al., 1998), it is likely
that this enzyme may inﬂuence the spatiotemporal dynam-
ics of retrograde signaling by endocannabinoids.
To obtain a complete assessment of FAAH’s potential
role in the regulation of endocannabinoid signaling, we
have performed an immunocytochemical analysis of FAAH
and CB1 expression throughout the mouse brain, using
FAAH-knockout mice to establish unequivocally the spec-
iﬁcity of FAAH-immunostaining in wild type animals. The
detailed analysis of FAAH and CB1 expression in the
mouse brain that we present here provides a neuroana-
tomical framework that will facilitate use of the mouse as a
model system for analysis of the physiological and behav-
ioral roles of the endocannabinoid signaling system.
EXPERIMENTAL PROCEDURES
Preliminary immunocytochemical analysis of FAAH and CB1 ex-
pression was performed using brains from mice of the BALB/c
strain to establish working methods prior to analysis of brains from
FAAH-knockout mice (FAAH
/) and their wild type littermates
(FAAH
/). FAAH
/ and FAAH
/ mice were produced from
intercrosses of 129SvJ-C57BL/6 FAAH
/ mice at the Scripps
Research Institute, as described by Cravatt et al. (2001). Three
pairs of mice were analysed at ages between 12 and 16 weeks:
680/681 (female, 16 weeks), 909/910 (male, 12 weeks) and 755/
762 (female, 16 weeks). Mice were asphyxiated with CO2 and
perfused through the heart with 25 ml of 4% paraformaldehyde in
phosphate-buffered saline (PBS), pH 7.4, as approved by the
Queen Mary, University of London Animal Care and Use Commit-
tee and by The Home Ofﬁce (UK). Moreover, the experimental
procedures used were designed to minimize the number of ani-
mals used and their suffering. Brains were removed and postﬁxed
in Bouin’s ﬁxative for at least 3 days at room temperature before
embedding in parafﬁn wax. Coronal and saggital sections (7 or 10
m) were cut using a Leica RM2145 microtome (Leica, Nussloch,
Germany), and sets of adjacent sections were collected at 0.5 mm
intervals through the brain and then mounted on glass slides
coated with 2% gelatin (w/v) in chrome alum solution. Dewaxed
sections were blocked with 3% normal goat serum/PBS with 0.2%
Triton X-100 (PBST) and then incubated with previously charac-
terized antibodies to a GST-fusion protein incorporating amino-
acid residues 38–579 of FAAH (Egertova ´ et al., 1998, 2000;
Cravatt et al., 2001), and used here at a dilution of 1:100 in PBST.
Bound antibodies were revealed using the ABC Elite kit (Vector
Laboratories, Peterborough, UK). To enable comparison of FAAH
expression with CB1 cannabinoid receptor expression, series of
brain sections adjacent to series that had been processed with
FAAH antibodies were tested immunocytochemically with a pre-
viously characterized antiserum (2825.3) to the C-terminal tail of
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2000; Egertova ´ et al., 1998) or with antibodies afﬁnity-puriﬁed
from the CB1-antiserum 2816.4 (see Egertova ´ and Elphick, 2000).
Low-magniﬁcation digital images (Fig. 1) of the immuno-
stained sections were captured using a Retiga 1300 12-bit mono-
chrome camera (Qimaging Corp., Burnaby, B.C., Canada) linked
to a Leica DMRA2 compound microscope (Leica, Nussloch, Ger-
many). OpenLab 3.0.8 (Improvision) software was used to import
images from the camera. High-magniﬁcation images (Figs. 2–9) of
immunostained sections were captured using a Hamamatsu dig-
ital camera linked to a Leica DMRD microscope (Leica, Wetzlar,
Germany). High Performance Image Control System (HiPic 32)
software was used to import images from the camera. Digital
images were processed using Adobe Photoshop software (ver-
sion 5.5), removing imperfections caused by dust particles, and
then labeled with reference to Paxinos and Franklin (2001).
RESULTS
General observations
Immunocytochemical analysis of FAAH expression in sec-
tions of wild type mouse brain revealed a pattern of immu-
nostaining (Fig. 1) that was generally consistent with the
distribution of FAAH mRNA expression in rat brain (Thom-
as et al., 1997). Moreover, to establish unequivocally the
speciﬁcity of the immunostaining observed with the FAAH
antibodies in the mouse brain, we analyzed brain sections
from FAAH
/ mice alongside brain sections from their
wild type littermates. Importantly, all of the immunostaining
seen in FAAH
/ mice with FAAH antibodies was absent
in FAAH
/ mice, as illustrated in Fig. 2A and B, respec-
tively. These ﬁndings demonstrate that the FAAH antibod-
ies used in this study are speciﬁc for FAAH under immu-
nocytochemical conditions, consistent with previous anal-
ysis of FAAH
/ mice and FAAH
/ mice (Cravatt et al.,
2001).
The majority of the FAAH-immunoreactivity in the
mouse brain was associated with neuronal somata and
their dendrites. However, in some regions of the brain
FAAH-immunoreactive cells were also present in ﬁber
tracts (white matter). This is consistent with the detection
of signals for FAAH mRNA in white matter of the rat brain,
as reported by Thomas et al. (1997). The morphology of
the FAAH-immunoreactive cells in ﬁber tracts of the mouse
brain indicates that these cells are oligodendrocytes (see
Fig. 8C). Consistent with this hypothesis, FAAH-immuno-
reactivity is also evident in the myelin sheath surrounding
the unstained axons of large neurons (Fig. 8C). Accord-
ingly, myelin sheath-associated FAAH probably accounts
for FAAH-immunoreactivity associated with several dis-
crete ﬁber tracts in several regions of the brain (e.g. see
caudate putamen, CPu in Fig. 1C).
In addition to neuronal and oligodendrocytic expres-
sion of FAAH, FAAH-immunoreactivity is also present in
ependymal cells that line the ventricles of the mouse brain
and this can be seen in the low magniﬁcation images of
Fig. 1 but it is more clearly seen at a higher magniﬁcation
in Fig. 7A. However, no CB1-immunoreactivity is associ-
ated with the FAAH-immunoreactivity in ependymal cells.
A detailed analysis of this feature of FAAH expression in
the mouse brain is beyond the scope of this paper but it will
be discussed in detail in a subsequent paper that will focus
speciﬁcally on the role of FAAH in the ventricular epithe-
lium (Egertova ´ et al., unpublished observations).
Here, for the ﬁrst time, we illustrate and compare the
distribution of FAAH and CB1 throughout the mouse brain
based on our analysis of brains from wild type mice
(BALB/c, n3; 129SvJ-C57BL/6, n3). Fig. 1 shows
FAAH-immunostaining (A, C, E, G, I, K, M, O, Q) and
CB1-immunostaining (B, D, F, H, J, L, N, P, R) in two series
of adjacent coronal sections of the brain of a single female
animal (no. 680; FAAH
/; 129SvJ-C57BL/6). The dis-
tance between consecutive sections in each series is ap-
proximately 1 mm. The images in Fig. 1 provide an over-
view of the distribution of FAAH and CB1 in the mouse
brain. Moreover, below we refer to the images in Fig. 1
when discussing in detail the distribution of FAAH and CB1
in different regions of the brain. Because of the limitations
of space, it is not feasible to describe and illustrate at high
magniﬁcation the distribution of FAAH and CB1 in all re-
gions of the mouse brain. Previously, we have described in
detail and illustrated the distribution of CB1 in the rat brain
(Egertova ´ and Elphick, 2000). Here we have focused on
FAAH, and below we describe in detail and illustrate at
higher magniﬁcation than the images in Fig. 1 those re-
gions of the brain where FAAH-expressing cells are par-
ticularly abundant (Figs. 2–9). Moreover, in those brain
regions where both FAAH and CB1 are expressed at high
levels we also show corresponding images of CB1-immu-
noreactivity in sections adjacent to images of sections
showing FAAH-immunoreactivity (Figs. 3–6).
Olfactory bulb and olfactory cortex
Inspection of Fig. 1A and B reveals that intense FAAH-
immunoreactivity is evident in the olfactory bulb (OB; Fig.
1A) compared with relatively low levels of CB1 expression
(Fig. 1B). More speciﬁcally and most noteworthy, FAAH is
particularly abundant in ﬁbers of the olfactory nerve (ON)
and in the olfactory glomeruli (Gl) (Fig. 2A). FAAH-immu-
noreactivity is also evident in the somata and dendrites of
mitral cells (Mi; Fig. 2A), consistent with previous analysis
of rat brain (Tsou et al., 1998). Relatively weak FAAH-
immunoreactivity can also be seen in the granule cell layer
(GrO) of the olfactory bulb (Fig. 2A).
FAAH-immunoreactive neuronal somata are evident in
the majority of the cortical olfactory regions that receive
direct input from the olfactory bulbs. These include the
anterior olfactory nucleus (AON; Figs. 1A, 3A), the piriform
cortex (Pir; Figs. 1C, E, G, I; 3C), the tenia tecta (DTT;
Figs. 1C; 3E) and the indusium griseum (IG; Fig. 1C, E),
and in all of these regions FAAH-immunoreactive neuronal
somata are surrounded by a complementary network of
CB1-immunoreactive ﬁbers (Figs. 1B, D, F, H, J; 3B, D, F).
FAAH-immunoreactive neurons are not, however, evident
in the olfactory tubercle, a region of the olfactory cortex
that contains a ﬁne meshwork of CB1-immunoreactive ﬁ-
bers in both mouse (not shown) and rat (Egertova ´ and
Elphick, 2000).
M. Egertova ´ et al. / Neuroscience 119 (2003) 481–496 483Fig. 1. The distribution of FAAH (left column; A, C, E, G, I, K, M, O, Q) and CB1 (right column; B, D, F, H, J, L, N, P, R) in a series of adjacent coronal
sections of the mouse brain as revealed by immunocytochemistry. Scale bar0.5 mm.
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Neuronal FAAH-immunoreactivity was detected in the lat-
eral septum (LS; Fig. 1E) and the triangular septal nucleus
(TS; Fig. 1G) with associated low-level expression of CB1
(Fig. 1F, H). FAAH-immunoreactive neuronal somata are
also present throughout the basolateral complex of the
amygdala, which includes the lateral (La), basolateral
(BLA, BLV) and basomedial (BMP) nuclei (Figs. 1I; 4A). In
all of these nuclei the FAAH-immunoreactive neuronal so-
mata are surrounded by CB1- immunoreactive ﬁbers (Figs.
1J; 4B).
Consistent with previous analysis of the rat brain
(Egertova ´ et al., 1998), FAAH-immunoreactivity was de-
tected in the somata and dendrites of pyramidal cells
throughout the hippocampus (Figs. 1I, K; 5A, E). In addi-
tion, however, FAAH-immunoreactivity is also evident in
the somata of dentate gyrus granule cells (DG; Figs. 1I, K;
GrDG; 5A, C). This is of particular interest because, al-
though FAAH mRNA has been detected in these cells in
Fig. 1. (Continued).
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ity is not evident in granule cells of the rat dentate gyrus
(Tsou et al., 1998; our unpublished observations). CB1-
immunoreactivity was detected in a dense meshwork of
ﬁbers surrounding both hippocampal pyramidal cells (Figs.
1J, K; 5B, F) and granule cells of the dentate gyrus (Figs.
1J, K; 5B, D), respectively, as in the rat brain (Egertova ´
and Elphick, 2000).
Cerebral cortex and cerebellar cortex
FAAH-immunoreactive neuronal somata are present
throughout transitional (e.g. orbital [O] cortex; Figs. 1A;
6C) and neocortical regions (e.g. primary somatosensory
[S1] cortex; Figs. 1C, E, G, I; 6A) of the cerebral cortex,
and are surrounded by CB1-immunoreactive ﬁbers (Figs.
1D, F; 6B, D). FAAH-immunoreactive neuronal somata are
evident in all layers except layer I, the most striking of
which are large cells present in layer V (Fig. 6A). CB1-
immunoreactivity is present in a network of ﬁbers in all
layers but the density of these ﬁbers is highest in layers II
and III, the outer region of layer V and throughout layer VI
with layers I, IV and V (inner) showing much sparser ﬁber
staining (Fig. 6B).
Consistent with previous analysis of the rat cerebellar
cortex (Egertova ´ et al., 1998), FAAH-immunoreactivity was
Fig. 1. (Continued).
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However, the dendritic branches of the Purkinje cells con-
tained little or no FAAH-immunoreactivity. FAAH-immuno-
reactivity was also evident in the somata of granule cells
(GrL), although the intensity of staining is quite weak (Fig.
6E). This is consistent with the detection of FAAH mRNA in
rat cerebellar granule cells (Thomas et al., 1997), although
in the rat FAAH-immunoreactivity is not evident in these
cells (Egertova ´ et al., 1998; Tsou et al., 1998). As in rat
brain, CB1-immunoreactivity was detected in the axon ter-
minals of basket cells surrounding Purkinje cell somata
and in a dense meshwork of ﬁbers in the molecular layer
(ML) surrounding Purkinje cell dendrites (Fig. 6F). CB1-
immunoreactivity in the molecular layer is largely associ-
ated with the parallel ﬁbers of granule cells, consistent with
CB1 mRNA expression in granule-cell somata (Matsuda et
al., 1993).
Thalamus
FAAH-immunoreactivity was detected in neuronal so-
mata in the majority of thalamic nuclei, including the
anterodorsal (AD; Figs. 1G; 7A), the anteroventral (AV;
Figs. 1G; 7A), the anteromedial (AM, Figs. 1G; 7A), the
ventroanterior (VA; Figs. 1G; 7A), the paratenial (PT;
Fig. 7A), the mediodorsal (MD; Figs. 1G, I; 7A, B), the
reticulothalamic (Rt; Figs. 1G; 7B), the ventrolateral (VL;
Fig. 7B), the ventroposterior (VP; Figs. 1I; 7B, C), the
ventromedial (VM; Figs. 1I; 7B), the posterior (Po; Figs.
1I; 7C), the lateral geniculate (LG; Fig. 7C) and the
medial geniculate (MG; 1K). Importantly, however, little
or no CB1-immunoreactivity was detected in the thala-
mus (Fig. 1H, J). This is consistent with the ﬁndings of
Herkenham et al. (1991) who detected only low concen-
trations of cannabinoid-binding sites in thalamic nuclei
Fig. 1. (Continued).
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of the brain where FAAH-immunoreactive neurons are
particularly abundant but with few or no associated CB1-
expressing ﬁbers.
Mid-brain
FAAH-immunoreactive neurons are present in the inferior
colliculus (IC; Figs. 1M; 8A), the superior colliculus (not
shown), the rhabdoid nucleus (Rbd; Figs. 1M; 8B), several
mesencephalic raphe nuclei (MnR, DR; Figs. 1M; 8B) and
the mesencephalic trigeminal nucleus (Me5; Fig. 8C). Little
or no CB1-immunoreactivity is evident in these regions of
the brain (Fig. 1L, N). Conversely, FAAH-immunoreactive
neurons were not evident, however, in the substantia nigra
pars reticulata (SNR; Fig. 1K), a region of the mid-brain
that contains a very high concentration of CB1-immunore-
activity in both mouse (Fig. 1L) and rat (Egertova ´ and
Elphick, 2000).
In the mid-brain, the expression of FAAH by oligoden-
drocytes is particularly striking. For example, in Fig. 8B
FAAH-immunoreactive oligodendrocytes associated with
ﬁber tracts (mlf; xscp) are abundant and more intensely
stained than the FAAH-immunoreactive neurons in the
raphe nuclei. Moreover, Fig. 8C shows a clear example of
a FAAH-immunoreactive oligodendrocyte with a process
that is continguous with FAAH-immunoreactive myelin
sheath surrounding unstained axons in the mesencephalic
trigeminal tract (me5).
Hind-brain
In the hind brain, in addition to FAAH-immunoreactivity
associated with the cerebellar cortex (see above), FAAH-
immunoreactive neurons are present in the hypoglossal
nucleus (12N; Figs. 1Q; 9A) and the inferior olive (IO; Figs.
1Q; 9B), but little or no CB1-immunoreactivity was evident
in these nuclei (Fig. 1R). FAAH-immunoreactivity was also
detected in the somata of neurons in the cerebellar nuclei
(Figs. 1O; 9C), which receive synaptic input from Purkinje
cell axons. In white matter surrounding the cerebellar nu-
clei, FAAH-immunoreactive oligodendrocytes are particu-
larly abundant (Fig. 9C) and Fig. 9C shows how much
more intensely stained these glial cells are compared to
neighbouring neurons. The cerebellar nuclei are, however,
void of CB1-immunoreactivity (Fig. 1P), consistent with the
absence of cannabinoid-binding sites in these nuclei in the
rat brain (Herkenham et al., 1991).
DISCUSSION
Here we report the ﬁrst detailed analysis of the distribution
of FAAH in the mouse brain, using FAAH
/ mice as
negative controls to provide an unequivocal determination
of the speciﬁcity of immunostaining in wild type animals.
The majority of FAAH in the mouse brain is associated with
neurons and it is the presence of FAAH in neurons that is
probably most directly relevant to endocannabinoid signal-
ing, as discussed below. An interesting feature of neuronal
FAAH-immunostaining in several regions of the brain was
that FAAH-immunoreactivity appears not to be conﬁned to
neuronal somata but also extends into surrounding areas
of neural tissue. This is most clearly seen in the hippocam-
pal formation where, although the highest concentration of
FAAH-immunoreactivity is clearly located in the somata of
hippocampal pyramidal cells and granule cells of the den-
tate gyrus, there is also widespread immunostaining in
adjacent layers that contain their axons and dendrites (Fig.
5A, C, E). The diffuse and homogeneous nature of this
staining suggests that it is not compartmentalized within
neuronal processes but is located extracellularly. One pos-
sibility is that this putative extracellular FAAH-immunore-
activity is an artifact of tissue preparation resulting from
lysis of FAAH-expressing neuronal somata. An alternative
and more intriguing explanation, however, is that it reﬂects
active secretion of FAAH (either in soluble or vesicle-
associated form) into the surrounding extracellular medium
by FAAH-expressing neurons.
Fig. 2. Localization of FAAH in the olfactory bulb of wild type
(FAAH
/) mouse brain (A) and absence of FAAH-immunoreactivity in
the olfactory bulb of a FAAH
/ mouse (B). (A) FAAH-immunoreac-
tivity is present in the axons of olfactory receptor neurons in the
olfactory nerve (ON) and in the glomerular layer (Gl). FAAH-immuno-
reactivity is also present in the somata of mitral cells (Mi) and in the
granule cell layer of the olfactory bulb (GrO). (B) Shows absence of
immunoreactivity with FAAH antibodies in the olfactory bulb of
FAAH
/-mice, demonstrating the speciﬁcity of FAAH-immunoreactiv-
ity observed in the olfactory bulbs and in other brain regions. Scale
bar100 m.
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FAAH-immunoreactive neurons of the entire mouse brain
were to be found in the mesencephalic trigeminal nucleus
(Me5), as shown in Fig. 8C. These neurons are of partic-
ular interest because they are functionally homologous to
sensory neurons of the dorsal root ganglia and they are the
only primary sensory neurons with cell bodies located
within the central nervous system (Holstege et al., 1995).
Fig. 3. Localization of FAAH-immunoreactivity (A, C, E) and CB1-immunoreactivity (B, D, F) in adjacent sections of regions of the olfactory cortex:
anterior olfactory nucleus (A, B), piriform cortex (C, D) and tenia tecta (E, F). In all three regions FAAH-immunoreactive neuronal somata (A, C, E)
are surrounded by CB1-immunoreactive ﬁbers (B, D, F). Scale bar50 m in A and B, 25 m in C and D, 67 m in E and F.
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jaw opening and closing reﬂexes and it will therefore be of
speciﬁc interest to investigate the functional signiﬁcance of
FAAH expression in their somata.
In addition to neuronal FAAH expression, FAAH is also
expressed by oligodendrocytes and ventricular ependymal
cells of the mouse brain. The functional signiﬁcance of
FAAH expression in these non-neuronal cells is not yet
known and therefore this study represents the starting
point for a new aspect of FAAH research. The association
of FAAH with oligodendrocytes in ﬁber tracts is, however,
of particular interest with respect to a recent study showing
that FAAH activity in the striatum is reduced in a rat model
of Parkinson’s disease in which inputs to the striatum from
the substantia nigra are disrupted (Gubellini et al., 2002).
We speculate that the loss of neuronal inputs to the stria-
tum from the substantia nigra may also lead to loss of
associated FAAH-expressing oligodendrocytes, which
could account for the reduced levels of striatal FAAH in
rats with experimental Parkinsonism.
To address the main objective of this study and assess
the potential role of FAAH in endocannabinoid signaling,
we have compared the distribution of FAAH with that of the
CB1 cannabinoid receptor throughout the mouse brain. We
have identiﬁed: (1) regions of the brain where FAAH is
expressed with little or no associated CB1; (2) regions of
the brain where there is expression of both FAAH and CB1;
and (3) regions of the brain where CB1 is expressed with
little or no associated FAAH. Below we will consider the
functional signiﬁcance of these ﬁndings and, in particular,
the potential role of FAAH in regulation of the spatiotem-
poral dynamics of retrograde signaling by endocannabi-
noids.
Regions of the brain where FAAH-expressing neurons
are present but accompanied by few or no CB1-expressing
ﬁbers include the thalamus, mid-brain and hind brain. In
some brain regions (e.g. hypoglossal nucleus, median ra-
phe nucleus), the absence of CB1-immunoreactivity may
simply reﬂect insensitivity of the immunocytochemical
methods used here because there is evidence for the
presence of low-level cannabinoid receptor expression
from radioligand binding studies (Herkenham et al., 1991).
However, there clearly are some regions of the brain (e.g.
thalamic nuclei, mesencephalic trigeminal nuclei, cerebel-
lar nuclei) where FAAH-immunoreactive neurons are wide-
spread but in the absence of associated CB1 expression.
In regions of the brain such as these, the role of FAAH is
likely to be unrelated to CB1-dependent endocannabinoid
signaling mechanisms. Intriguingly, it is possible that in
these regions of the brain, FAAH participates in regulation
of signaling mediated by a novel G protein coupled anan-
damide receptor discovered recently in the brains of
CB1
/ mice (Breivogel et al., 2001). Alternatively, in these
regions of the brain FAAH may be involved in inactivation
of fatty acid amide signaling molecules that exert their
effects via non-cannabinoid receptors. For example, there
is evidence that oleamide exerts effects in the thalamus via
allosteric interaction with the serotonin 5-HT7 receptor
(Thomas et al., 1999) and the presence of FAAH in tha-
lamic neurons may regulate the actions of this sleep-in-
ducing lipid.
More typically, however, FAAH and CB1 are anatomi-
cally associated, with FAAH-immunoreactive neuronal so-
mata surrounded by CB1-immunoreactive ﬁbers, as re-
ported previously in the rat cerebellar cortex, hippocampus
and neocortex (Egertova ´ et al., 1998). Based on this ana-
tomical relationship between FAAH and CB1 expression,
we predicted that endocannabinoids may act as retrograde
signaling molecules at synapses in the brain (Egertova ´e t
al., 1998; Elphick and Egertova ´, 2001) and experimental
studies on the hippocampus and cerebellar cortex have
proved that this hypothesis was correct (Kreitzer and Re-
gehr, 2001a,b; Maejima et al., 2001a,b; Ohno-Shosaku et
al., 2001; Wilson and Nicoll, 2001; Wilson et al., 2001).
Therefore, it seems likely that endocannabinoids may also
act as retrograde messengers at synapses in the many
Fig. 4. Localization of FAAH immunoreactivity (A) and CB immunoreactivity (B) in the basolateral complex of the amygdala showing that FAAH-
immunoreactive neuronal somata are surrounded by CB1-immunoreactive ﬁbers. A and B show FAAH (A) and CB1 (B) immunoreactivity in
low-magniﬁcation images of adjacent sections of the amygdala. The inset of A shows detail of FAAH-immunoreactive neuronal somata in BMP whilst
the inset of B shows detail of CB1-immunoreactive ﬁbers in LaVM. Scale bar100 m in A and B, and to 16 m in the insets of A and B.
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mentary” expression of FAAH and CB1 occurs, which in-
clude the olfactory cortex, amygdala, dentate gyrus, tran-
sitional cortex and neocortex. Moreover, it is important to
Fig. 5. Localization of FAAH-immunoreactivity (A, C, E) and CB1-immunoreactivity (B, D, F) in the hippocampal formation. A and B show FAAH (A)
and CB1 (B) immunoreactivity in low-magniﬁcation images of adjacent sections of the hippocampus (CA1–CA3) and the dentate gyrus (DG). (C) Detail
of FAAH-immunoreactivity in the dentate gyrus showing that whilst FAAH is concentrated in the granule cell layer, diffuse and homogeneous
immunoreactivity is also evident throughout the molecular layer, which may reﬂect active secretion of the enzyme (see discussion). (D) Detail of CB1
immunoreactivity in the dentate gyrus showing that immunoreactive ﬁbers are present surrounding the unstained somata of granule cells (GrDG) and
throughout the molecular layer (MoDG) where the dendrites of granule cells arborize. (E) Detail of FAAH-immunoreactivity in the hippocampus
showing that FAAH is concentrated in the somata of pyramidal cells but is also present in adjacent layers. (F) Detail of CB1-immunoreactivity in the
pyramidal cell layer of the hippocampus showing that immunoreactive ﬁbers are present surrounding the unstained somata of pyramidal cells. Scale
bar111 m in A and B, 25 m in C and D and 10 m in E and F.
M. Egertova ´ et al. / Neuroscience 119 (2003) 481–496 491Fig. 6. Localization of FAAH-immunoreactivity (A, C, E) and CB1-immunoreactivity (B, D, F) in cerebral cortex and cerebellar cortex. A and B show
adjacent sections of primary somatosensory cortex, as a representative region of neocortex. FAAH-immunoreactive neuronal somata are present in
all layers of the cortex except layer I but large cells in layer V are more intensely stained than cells in other layers. CB1- immunoreactive ﬁbers are
present in all layers of the neocortex surrounding unstained neuronal somata. However, the density of CB1-immunoreactive ﬁbers is highest in layers
II, III, V-outer and VI whilst layers I, IV and V-inner contain fewer immunoreactive ﬁbers. C and D show adjacent sections of medial orbital cortex, as
a representative region of transitional cortex. Note the complementary pattern of FAAH and CB1 expression with CB1-immunoreactive ﬁbers (inset of
D) surrounding FAAH-immunoreactive neuronal somata (inset of C). (E) Purkinje cells in the Purkinje cell layer (PCL) of the cerebellar cortex are
strongly FAAH-immunoreactive whilst cells of the granule cell layer (GrL) display weak FAAH-immunoreactivity. (F) CB1-immunoreactivity in the
cerebellar cortex is complementary to FAAH, with intense immunostaining in ﬁbers of the molecular layer (ML) and in the axon terminals of basket cells
(arrows). Scale bar100 m in A and B, 50 m in C and D, 15 m in the insets of C and D, and 25 m in E and F.
M. Egertova ´ et al. / Neuroscience 119 (2003) 481–496 492Fig. 7. Localization of FAAH-immunoreactivity in thalamic nuclei. (A)
FAAH- immunoreactive neuronal somata in the anterodorsal (AD), the
anteroventral (AV), the anteromedial (AM), paratenial (PT), the me-
diodorsal (MD) and reticulothalamic (Rt) nuclei. Note also the immu-
nostaining in ependymal cells lining the dorsal third ventricle (D3V)
and the absence of immunostaining in the stria medullaris (sm). (B)
FAAH-immunoreactive neuronal somata in the mediodorsal (MD), the
reticulothalamic (Rt), the ventrolateral (VL), the ventroposterior (VP)
and the ventromedial (VM) nuclei. The inset shows FAAH-immunore-
active neuronal somata in the ventroposterior thalamic nucleus at high
magniﬁcation. (C) FAAH-immunoreactive neuronal somata in the VP,
the posterior (Po) and the lateral geniculate (LG) nuclei. Scale
bar100 mi nA ,1 5 4mi nB ,2 5m in the inset of B and 56 mi nC .
Fig. 8. FAAH-immunoreactivity in mid-brain regions. (A) FAAH-immu-
noreactive neurons in the inferior colliculus. (B) FAAH-immunoreactive
neurons in the rhabdoid nuclei (Rbd) and the median (MnR) and dorsal
(DR) raphe nuclei. Note the intensely stained cells (oligodendrocytes)
in ﬁber tracts of the decussation of the superior cerebellar peduncle
(xscp) and the medial longitudinal fasciculus (mlf). (C) FAAH-immu-
noreactive neuronal somata in a saggital section through the mesen-
cephalic trigeminal nucleus (Me5). Note also the strongly stained
oligodendrocyte (arrow) with a process projecting into a ﬁber bundle of
the mesencephalic trigeminal tract (me5). The ﬁbrous staining in me5
appears to be localized in the myelin sheath surrounding the unstained
axons of Me5 neurons, consistent with FAAH expression by oligoden-
drocytes. Scale bar50 m in A and B and to 25 mi nC .
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grade signaling by endocannabinoids at synapses.
In analyzing the spatial dynamics of retrograde signal-
ing by endocannabinoids in the hippocampus, Wilson and
Nicoll (2001) conclude that their effects are restricted to a
sphere with a diameter of about 40 m surrounding the
pyramidal cell to which a depolarizing stimulus has been
applied. Moreover, Carlson et al. (2002) have found that
release of endocannabinoids by a pyramidal cell causes a
normally ineffective train of excitatory post-synaptic cur-
rents to induce long-term potentiation (LTP) in that cell but
not in neighbouring cells. Because FAAH is located in the
somata and dendrites of hippocampal pyramidal cells, the
activity of this enzyme is likely to be a key determinant of
the distance over which endocannabinoids diffuse from a
cellular site of synthesis before being inactivated. Thus,
the presence of FAAH in pyramidal cell somata may con-
ﬁne endocannabinoid-facilitated LTP to cells in which en-
docannabinoid biosynthesis has been triggered. Moreover,
FAAH probably exerts such a regulatory role in the spatial
dynamics of retrograde signaling by endocannabinoids not
only in the hippocampus but also in the many regions of
the brain that we describe here where FAAH is located in
neuronal somata and/or dendrites surrounded by CB1-
immunoreactive ﬁbers. For example, a complementary
pattern of FAAH and CB1 expression like that seen in the
hippocampus is also evident in the cortex of the forebrain
and in subcortical regions such as the amygdala. Accord-
ingly, several recent studies indicate that endocannabi-
noids also act as retrograde synaptic signaling molecules
in these regions of the forebrain (Katona et al., 2001;
Trettel and Levine, 2002).
FAAH is likely to inﬂuence not only the spatial dynam-
ics of cannabinoid signaling but also the temporal dynam-
ics. Evidence for such a role is apparent in the cerebellar
cortex where endocannabinoids mediate retrograde sup-
pression of both excitatory and inhibitory synapses onto
Purkinje cells (Kreitzer and Regehr, 2001a,b; Maejima et
al., 2001b). Here FAAH is located in Purkinje cell somata,
whilst CB1 is located on the presynaptic terminals of gran-
ule cells (glutamatergic parallel ﬁbers), basket cells
(GABAergic) and probably also climbing ﬁbers (glutama-
tergic). Depolarization of Purkinje cells causes transient
endocannabinoid-mediated inhibition of excitatory inputs
from parallel ﬁbers and climbing ﬁbers with maximal inhi-
bition occurring after approximately 5 s, followed by a
gradual restoration of basal excitatory input within 50 s
(Kreitzer and Regehr, 2001a). Because FAAH is located in
the somato-dendritic compartment of Purkinje cells, the
duration of the inhibitory action of Purkinje cell-derived
endocannabinoids is likely to be largely inﬂuenced by up-
take and FAAH-mediated inactivation of endocannabi-
noids in Purkinje cells.
Importantly, the dynamics of retrograde endocannabi-
noid signaling may be inﬂuenced not only by the presence
of FAAH in the somata of neurons that are postsynaptic to
CB1-expressing ﬁbers but also by the expression of FAAH
by other nearby cells. For example, in the cerebellar cortex
the presence of FAAH in the somata of granule cells may
inﬂuence the dynamics of retrograde signaling from the
principal cells (Purkinje cells) to the presynaptic terminals
of parallel ﬁbers, climbing ﬁbers and basket cells. Con-
versely, in the olfactory bulb, retrograde endocannabinoid
signaling may operate at the synapses between CB1-im-
munoreactive projection neurons from the anterior olfac-
tory nucleus and FAAH-immunoreactive granule cells.
Fig. 9. FAAH-immunoreactivity in hind-brain regions. (A) FAAH-im-
munoreactive neurons in the hypoglossal nucleus (12N). (B) FAAH-
immunoreactive neurons in the dorsomedial cell group (IODM), the
medial nucleus (IOM), the dorsal nucleus (IOD) and the principal
nucleus (IOPr) of the inferior olive, dorsal to the pyramidal tract (py).
(C) FAAH-immunoreactive neurons in the posterior interposed cere-
bellar nucleus (IntP), the medial cerebellar nucleus (Med) and the
dorsolateral protruberance of the medial cerebellar nucleus (MedDL).
Note also the intensely stained small cells (oligodendrocytes) in the
cerebellar nuclei and surrounding white matter (wm). Scale bar50
mi nA ,Ba n dC .
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be inﬂuenced by the presence of FAAH in principal cells of
the olfactory bulb (mitral cells). Moreover, in mouse olfac-
tory bulbs FAAH is also present in ﬁbers of the olfactory
nerves that project into the olfactory bulb glomeruli where
they form synapses with the glomerular dendrites of mitral
cells. This is of particular interest because it is the ﬁrst
example, to the best of our knowledge, where FAAH is
targeted to the axonal compartment of neurons because in
all other regions of the mouse and rat brain it is targeted to
the somato-dendritic compartment of neurons. It also pro-
vides a unique example of a synapse where FAAH is
located both presynaptically (olfactory-receptor neuron ter-
minals) and postsynaptically (mitral cells). The functional
signiﬁcance of this complex pattern of expression is not yet
clear, but it may reﬂect the unusual synaptic organization
of olfactory glomeruli (see Shepherd and Greer, 1998).
The distribution of CB1 in the brain, although strikingly
complementary with FAAH in many regions of the fore-
brain and in the cerebellar cortex, is not always associated
with FAAH-expressing neurons. For example, there is a
population of striatal GABAergic medium-spiny projection
neurons that target the CB1 receptor to their axonal termi-
nals in globus pallidus (GP), entopeduncular nucleus (EP)
and substantia nigra pars reticulata (SNR). The density of
CB1 receptors in these output nuclei is particularly high
(Fig. 1H, J, L), whilst FAAH-expressing neurons are sparse
or absent (Fig. 1G, I, K). This may in part simply reﬂect the
neuroarchitecture of these brain regions, but nevertheless
it is of interest to consider the mechanisms of cannabinoid
signaling at striatal output synapses. A recent study by
Wallmichrath and Szabo (2002) demonstrated that canna-
binoids inhibit release of GABA by striatonigral axons and,
moreover, depolarization of SNR neurons causes endo-
cannabinoid-mediated suppression of GABAergic inhibi-
tory postsynaptic currents. These data indicate that endo-
cannabinoids mediate retrograde signaling from SNR neu-
rons to the presynaptic CB1-expressing axons of
striatonigral neurons. Interestingly, because SNR neurons
do not appear to express FAAH, the dynamics of retro-
grade endocannabinoid signaling at these synapses may
be different to synapses where FAAH is expressed
postsynaptically (e.g. hippocampal pyramidal cells) and
further experimental analysis is now required to address
this issue.
In conclusion, this study provides a neuroanatomical
basis for future investigations of endocannabinoid signal-
ing at synapses in many regions of the brain. In particular,
our data suggest that the dynamics of endocannabinoid
signaling may be directly inﬂuenced by the occurrence and
relative abundance of FAAH in neurons. Moreover, the
identiﬁcation of FAAH-immunoreactive neurons without
associated CB1 cannabinoid receptor expression may
pave the way for functional analysis of fatty acid amide
signaling pathways mediated by other receptors.
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